Compare SHASUN PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AJANTA PHARMA SHASUN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 123.9 22.1 560.9% View Chart
P/BV x 8.5 3.8 224.2% View Chart
Dividend Yield % 0.2 0.9 25.2%  

Financials

 SHASUN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AJANTA PHARMA
Mar-19
SHASUN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs941,422 6.6%   
Low Rs46898 5.1%   
Sales per share (Unadj.) Rs214.2233.5 91.7%  
Earnings per share (Unadj.) Rs5.344.0 12.1%  
Cash flow per share (Unadj.) Rs15.852.2 30.3%  
Dividends per share (Unadj.) Rs1.009.00 11.1%  
Dividend yield (eoy) %1.40.8 184.4%  
Book value per share (Unadj.) Rs53.3255.1 20.9%  
Shares outstanding (eoy) m56.6288.02 64.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.35.0 6.6%   
Avg P/E ratio x13.126.4 49.7%  
P/CF ratio (eoy) x4.422.2 19.9%  
Price / Book Value ratio x1.34.5 28.8%  
Dividend payout %18.720.5 91.5%   
Avg Mkt Cap Rs m3,958102,081 3.9%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1644,307 50.2%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m12,12720,554 59.0%  
Other income Rs m229211 108.8%   
Total revenues Rs m12,35620,765 59.5%   
Gross profit Rs m1,0095,664 17.8%  
Depreciation Rs m594721 82.4%   
Interest Rs m41512 3,578.4%   
Profit before tax Rs m2305,143 4.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,273 -5.7%   
Profit after tax Rs m3023,870 7.8%  
Gross profit margin %8.327.6 30.2%  
Effective tax rate %-31.724.8 -127.9%   
Net profit margin %2.518.8 13.2%  
BALANCE SHEET DATA
Current assets Rs m6,88411,812 58.3%   
Current liabilities Rs m8,4563,776 223.9%   
Net working cap to sales %-13.039.1 -33.1%  
Current ratio x0.83.1 26.0%  
Inventory Days Days6277 79.6%  
Debtors Days Days10882 131.8%  
Net fixed assets Rs m4,97014,398 34.5%   
Share capital Rs m113175 64.6%   
"Free" reserves Rs m2,87522,277 12.9%   
Net worth Rs m3,02022,452 13.5%   
Long term debt Rs m1,8177 27,536.4%   
Total assets Rs m13,34726,962 49.5%  
Interest coverage x1.6444.3 0.3%   
Debt to equity ratio x0.60 204,704.7%  
Sales to assets ratio x0.90.8 119.2%   
Return on assets %5.414.4 37.3%  
Return on equity %10.017.2 58.0%  
Return on capital %13.323.0 58.1%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84310,682 54.7%   
Fx outflow Rs m2,1732,102 103.4%   
Net fx Rs m3,6698,580 42.8%   
CASH FLOW
From Operations Rs m3983,748 10.6%  
From Investments Rs m-1,635-2,228 73.4%  
From Financial Activity Rs m1,309-1,475 -88.7%  
Net Cashflow Rs m7145 157.5%  

Share Holding

Indian Promoters % 39.2 73.8 53.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 1.6 232.3%  
FIIs % 17.6 7.6 231.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.0 232.9%  
Shareholders   20,750 20,968 99.0%  
Pledged promoter(s) holding % 12.3 4.4 280.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS